Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics (IPSC) filing notifies a proposed sale under Rule 144 of 30,745 common shares with an aggregate market value of $17,521.58. The shares represent restricted stock that vested and were acquired on 08/15/2025 and the filer intends to sell on or about 08/18/2025 through Fidelity Brokerage Services on NASDAQ. The filing shows 86,389,098 shares outstanding for the issuer. It also discloses a prior sale by the same person of 475 shares on 06/09/2025 for $295.50. The acquisition payment is listed as compensation. The signer certifies no undisclosed material adverse information.
Brent Pfeiffenberger, President and CEO and a director of Century Therapeutics, Inc. (IPSC), received a grant of 1,587,614 restricted stock units (RSUs) on 08/14/2025. Each RSU converts into one share of common stock and will settle in shares on vesting. The RSUs vest 50% on August 14, 2027 and the remaining 50% on August 14, 2028, each tranche conditioned on continued service through the vesting date. The reported transaction shows an acquisition at a reported price of $0 and indicates 3,269,397 shares beneficially owned by the reporting person after the transaction. The Form 4 was filed for this single reporting person and signed by an attorney-in-fact on 08/18/2025.
Century Therapeutics (IPSC) reported operational updates reflecting continued development of its iPSC-derived cell therapy pipeline and recent acquisition activity. The company disclosed 86,322,071 shares outstanding at June 30, 2025 versus 85,836,429 at December 31, 2024. Century completed the acquisition of Clade, issuing 3,741,646 common shares at close and recording holdback shares of up to 793,687 subject to indemnification adjustments. Contingent consideration at closing included a fair-value amount of $2,600 plus a potential Clade milestone valued at $8,883, and a possible milestone payment of $10,000 payable in cash, shares, or combination.
The filing outlines program progress and capabilities including lead candidate CNTY-101, preclinical programs from Clade, and additional CAR-iT candidates (CNTY-308, CNTY-341) using the company’s Allo-Evasion™ and iPSC platforms. The company reported prior ATM sales of 4,084,502 shares for net proceeds of $17,829 in the six months ended June 30, 2024 and no ATM sales in the six months ended June 30, 2025. Quarter-over-quarter operating expense shifts include G&A of $7.8M versus $8.3M in the prior-year quarter and mixed R&D and facility cost changes driven by staff reductions, consolidation of lab operations, and completion of a manufacturing campaign under the FCDI collaboration.